The C-MORE study is prospective observational holistic longitudinal study which will characterise the prevalence of multi-organ injury among COVID-19 survivors post hospital discharge and assess its effects on quality of life, exercise tolerance and mental health.
Since the outbreak of Coronavirus disease (COVID-19), hundreds of thousands of lives have
been lost and millions significantly affected. Although primarily a respiratory viral
illness, emerging data suggests that multiorgan involvement is common in those with
moderate-severe infections. Whether or not persistent multiorgan damage will be seen in
COVID-19 survivors is unknown.
C-MORE is an observational study that aims to investigate the long-term effects of COVID-19
on the lungs, heart, brain, liver and kidneys using advanced state-of-the art magnetic
resonance imaging (MRI) technology. The study will assess 616 patients with
laboratory-confirmed COVID-19 from leading UK centres and undertake multi-organ magnetic
resonance imaging at 3, 6, and 12 months following the onset of COVID-19 symptoms. In
addition, assessments of breathing, exercise capacity, cognition and mental health will be
carried out.
The study will describe the prevalence of persistent multi-organ injury in COVID-19 patients
and assess how this relates to comorbid conditions, severity of acute respiratory illness,
immunological response, genetic factors, quality of life and mental health.
Diagnostic Test: Magnetic Resonance Imaging
We will undertake multi-organ MRI to assess the health of vital organs including the brain, heart, lung, kidneys and liver. We will additionally examine the burden of ongoing respiratory limitations, mental health problems and quality of life in survivors of COVID-19 at 3, 6 and 12 months.
Other Name: Array
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the
study.
- Male or Female, aged 18 years or above.
- Diagnosis of COVID-19 infection confirmed by detection of viral nucleic acid on
reverse-transcription Polymerase Chain Reaction (RT-PCR).
- Infection should be of moderate to severe intensity (i.e, patients with clinical signs
of pneumonia such as respiratory rate > 30 breaths/min; or severe respiratory
distress; or SpO2 < 90% (on room air) and admission for >48 hours.
Exclusion Criteria:
University of Oxford
Oxford, United Kingdom
Investigator: Betty Raman, MBBS, FRACP, DPhil
Contact: 0186534580
betty.raman@cardiov.ox.ac.uk
Investigator:
Betty Raman, MBBS, DPhil, FRACP
01865234580 - +44
betty.raman@cardiov.ox.ac.uk